Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready
Avalyn Pharma Inc. faces 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 5 distinct examiners across 4 distinct art units, showing some concentration of subject matter within specific USPTO groups. The presence of 6 actions across 4 art units implies that while the technology is specialized, it touches upon several different examination specialties.
The busiest examiner for this portfolio is PINDERSKI, JACQUELINE M, who oversees 2 pending office actions. This examiner manages more actions than any of the other 5 distinct examiners who each handle the remaining actions. Practitioners should prioritize understanding the specific tendencies of PINDERSKI, JACQUELINE M, as her decisions impact multiple pending actions. Navigating 4 distinct art units requires a strategy that accounts for the varying procedural expectations of different biotechnology groups. This concentration under a single examiner for a portion of the docket may allow for a more focused approach on those specific cases.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PINDERSKI, JACQUELINE M | 2 | 26.8% | +45.4% |
| ZHANG SPIERING, DONGXIU | 1 | 41.2% | +65.2% |
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
| TRUONG, QUANGLONG N | 1 | 78.6% | +23.3% |
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042375 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | PINDERSKI, JACQUELINE M | 104d overdue |
| 18171930 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | PINDERSKI, JACQUELINE M | 96d overdue |
| 17028595 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | HAGHIGHATIAN, MINA | 45d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042375 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | PINDERSKI, JACQUELINE M | 104d overdue |
| 18171930 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | PINDERSKI, JACQUELINE M | 96d overdue |
| 17028595 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | HAGHIGHATIAN, MINA | 45d overdue |
| 18974588 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | ZHANG SPIERING, DONGXIU | — |
| 18887514 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | RONEY, CELESTE A | — |
| 18664718 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | TRUONG, QUANGLONG N | — |
| Art Unit | Apps |
|---|---|
| 1616 | 2 |
| 3785 | 2 |
| 1612 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18974588 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | ZHANG SPIERING, DONGXIU | 1616 | §103§112DP | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18887514 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | RONEY, CELESTE A | 1612 | §103§112DP | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18664718 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | TRUONG, QUANGLONG N | 1615 | DP | Non-Final OA | — | Pending | May 15, 2024 |
| 18042375 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | PINDERSKI, JACQUELINE M | 3785 | §103§112 | Final Rejection | 104d overdue | Pending | Feb 21, 2023 |
| 18171930 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | PINDERSKI, JACQUELINE M | 3785 | §103 | Final Rejection | 96d overdue | Pending | Feb 21, 2023 |
| 17028595 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | HAGHIGHATIAN, MINA | 1616 | §103§112 | Final Rejection | 45d overdue | Pending | Sep 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAvalyn Pharma Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Jacqueline M Pinderski has the most, with 2 of Avalyn Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
